Global Blood Therapeutics Inc. (GBT)

48.75
1.49 2.97
NASDAQ : Health Technology
Prev Close 50.24
Open 50.00
Day Low/High 48.21 / 50.23
52 Wk Low/High 30.15 / 64.94
Volume 898.31K
Avg Volume 772.60K
Exchange NASDAQ
Shares Outstanding 60.23M
Market Cap 2.91B
EPS -3.40
P/E Ratio N/A
Div & Yield N.A. (N.A)
The Confidence in the Dip Buyers Has Weakened

The Confidence in the Dip Buyers Has Weakened

The bears are likely to be increasingly bold if there's a failed bounce.

This Market Badly Needs a Rest

This Market Badly Needs a Rest

It would be a longer-term positive if the overbought conditions are alleviated.

The Stock Market Is Facing One Big Obstacle Right Now

The Stock Market Is Facing One Big Obstacle Right Now

You have to wonder how much longer we can run without a pullback of at least 2%.

Selling Action Is Upon Us

Selling Action Is Upon Us

There is still a very strong appetite for individual stocks with momentum.

Notable Tuesday Option Activity: GBT, SFM, CROX

Notable Tuesday Option Activity: GBT, SFM, CROX

Looking at options trading activity among components of the Russell 3000 index, there is noteworthy activity today in Global Blood Therapeutics Inc , where a total volume of 6,399 contracts has been traded thus far today, a contract volume which is representative of approximately 639,900 underlying shares (given that every 1 contract represents 100 underlying shares). That number works out to 43.1% of GBT's average daily trading volume over the past month, of 1.5 million shares.

GBT Receives FDA Breakthrough Therapy Designation For Voxelotor For Treatment Of Sickle Cell Disease (SCD)

GBT Receives FDA Breakthrough Therapy Designation For Voxelotor For Treatment Of Sickle Cell Disease (SCD)

Voxelotor is First Investigational Treatment for SCD to Receive Breakthrough Therapy Designation

First Week Of GBT February 2018 Options Trading

First Week Of GBT February 2018 Options Trading

Investors in Global Blood Therapeutics Inc saw new options begin trading this week, for the February 2018 expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the GBT options chain for the new February 2018 contracts and identified one put and one call contract of particular interest.

GBT Announces New Phase 2a Data At ASH For Voxelotor In Adolescents With Sickle Cell Disease (SCD)

GBT Announces New Phase 2a Data At ASH For Voxelotor In Adolescents With Sickle Cell Disease (SCD)

Data to be Highlighted in ASH Press Briefing and Company to Host Investor Webcast on Monday, December 11, at 8:15 p.m. ET/5:15 p.m. PT to Discuss Data

Focused on Stock Picking Through This Volatility

Focused on Stock Picking Through This Volatility

I'm trying not to be sucked into the market-timing game and am looking mainly at setups in individual stocks.

The Return of Stock Market Volatility Can Create Stellar Opportunities

The Return of Stock Market Volatility Can Create Stellar Opportunities

But you need to be selective and have discipline.

Global Blood Therapeutics Announces Completion Of Safety Review By Independent Data And Safety Monitoring Board (DSMB) For Phase 3 HOPE Study In Sickle Cell Disease

Global Blood Therapeutics Announces Completion Of Safety Review By Independent Data And Safety Monitoring Board (DSMB) For Phase 3 HOPE Study In Sickle Cell Disease

Based on DSMB Review, Patients Age 12 to 17 Can Now be Enrolled in Phase 3 HOPE Study

Markets Get Back to Business as Usual

Markets Get Back to Business as Usual

U.S. stocks move higher after early slip, as investors digest Apple's latest results.

Noteworthy Friday Option Activity: GBT, XPER, USCR

Noteworthy Friday Option Activity: GBT, XPER, USCR

Looking at options trading activity among components of the Russell 3000 index, there is noteworthy activity today in Global Blood Therapeutics Inc , where a total volume of 4,743 contracts has been traded thus far today, a contract volume which is representative of approximately 474,300 underlying shares (given that every 1 contract represents 100 underlying shares). That number works out to 44.6% of GBT's average daily trading volume over the past month, of 1.1 million shares.

GUERBET : Revenue At September 30, 2017

GUERBET : Revenue At September 30, 2017

First Week of GBT June 2018 Options Trading

First Week of GBT June 2018 Options Trading

Investors in Global Blood Therapeutics Inc saw new options begin trading this week, for the June 2018 expiration. One of the key inputs that goes into the price an option buyer is willing to pay, is the time value, so with 233 days until expiration the newly trading contracts represent a potential opportunity for sellers of puts or calls to achieve a higher premium than would be available for the contracts with a closer expiration.

DBV Shares Fall After Phase 3 Data on Peanut Allergy Treatment -- Biotech Movers

DBV Shares Fall After Phase 3 Data on Peanut Allergy Treatment -- Biotech Movers

The Montrouge, France-based firm on Friday unveiled top-line results from its Phase 3 study of a peanut allergy treatment. The study, dubbed Pepites, evaluated Viaskin Peanut in children four to 11 years old.